Loading
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Latest quote
$2.62
+$0.24 · +10.08%
After-hours
$2.62
$0.00 · 0.00%
Oct 9, 4:01 PM ET
Regular session · ET · Market data may be delayed.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Day range
Current $2.62
52-week range
Current $2.62
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
48
Mixed
Risk
76
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Day range
Current $2.62
52-week range
Current $2.62
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.4M USD | 1.51M USD | 1.18M USD | — | — |
| Gross profit | −1.4M USD | −1.51M USD | −1.18M USD | — | — |
| Research and development | 71.04M USD | 76.48M USD | 68.13M USD | 54.08M USD | 23.8M USD |
| Selling, general, and administrative | 22.57M USD | 21.26M USD | 16.64M USD | 14.22M USD | 8.11M USD |
| Operating expenses | 92.22M USD | 96.23M USD | 83.58M USD | 68.3M USD | 27.11M USD |
| Interest income | 4.02M USD | 7.14M USD | 6.4M USD | 2.79M USD | — |
| Depreciation and amortization | 1.4M USD | 1.51M USD | 1.18M USD | 493K USD | 178K USD |
| Operating income | −93.61M USD | −97.74M USD | −84.77M USD | −68.3M USD | −27.11M USD |
| Net income | −89.66M USD | −89.98M USD | −78.63M USD | −69.1M USD | −27.28M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.21M0.00%2.3T USD0.03%$381.92+0.62%
Vanguard Extended Market ETFVXF1.56M0.00%95.4B USD0.05%$235.04+0.82%
iShares Biotechnology ETFIBB1.17M0.01%10.41B USD0.44%$206.49+3.00%
iShares Micro-Cap ETFIWC317.42K0.02%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM200K0.17%116.54M USD0.73%$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC102.24K—3.06B USD0.25%$69.98+0.03%
Dimensional - US Small Cap ETFDFAS53.23K0.00%33.8B USD0.31%$78.35+0.32%
U.S. Vector Equity Portfolio ETF Class SharesDXUV48.43K0.00%6.17B USD0.26%$68.24+0.19%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCDimensional - US Small Cap ETFDFASU.S. Vector Equity Portfolio ETF Class SharesDXUVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
